NCT00225303View on ClinicalTrials.gov

TMC125-C227: A Phase II Randomized, Active-Controlled, Open Label Trial to Investigate the Efficacy and Tolerability of TMC125 in HIV-1 Infected Subjects, Who Are PI-Naive and With Documented Genotypic Evidence of NNRTI Resistance From Previous NNRTI Use

PHASE2CompletedINTERVENTIONAL

Enrollment

116

Participants

Timeline

Start Date

March 31, 2005

Study Completion Date

June 30, 2006

Conditions

HIV Infection

Interventions

DRUG

TMC125

All Listed Sponsors

lead

Tibotec Pharmaceuticals, Ireland

INDUSTRY

NCT00225303 - TMC125-C227: A Phase II Randomized, Active-Controlled, Open Label Trial to Investigate the Efficacy and Tolerability of TMC125 in HIV-1 Infected Subjects, Who Are PI-Naive and With Documented Genotypic Evidence of NNRTI Resistance From Previous NNRTI Use | Biotech Hunter | Biotech Hunter